CLINICAL RESEARCH: HYPERTROPHIC AND DILATED CARDIOMYOPATHY
Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy
Iacopo Olivotto, MD*,*,
Martin S. Maron, MD ,
A. Selcuk Adabag, MD ,
Susan A. Casey, RN,
Daniela Vargiu, RN*,
Mark S. Link, MD,
James E. Udelson, MD,
Franco Cecchi, MD* and
Barry J. Maron, MD, FACC
* Regional Referral Center for Myocardial Diseases, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts-New England Medical Center, Boston, Massachusetts.
Manuscript received December 7, 2004;
revised manuscript received January 20, 2005,
accepted April 13, 2005.
* Reprint requests and correspondence: Dr. Iacopo Olivotto, Cardiologia San Luca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini 17, 50132, Firenze, Italy. (Email: olivottoi{at}ao-careggi.toscana.it).
OBJECTIVES: The goal of this study was to assess gender-related differences in a multicenter population with hypertrophic cardiomyopathy (HCM).
BACKGROUND: Little is known regarding the impact of gender on the heterogeneous clinical profile and clinical course of HCM.
METHODS: We studied 969 consecutive HCM patients from Italy and the U.S. followed over 6.2 ± 6.1 years.
RESULTS: Male patients had a 3:2 predominance (59%), similar in Italy and the U.S. (p = 0.24). At initial evaluation, female patients were older and more symptomatic than male patients (47 ± 23 years vs. 38 ± 18 years; p < 0.001; mean New York Heart Association [NYHA] functional class 1.8 ± 0.8 vs. 1.4 ± 0.6; p < 0.001), and more frequently showed left ventricular outflow obstruction (37% vs. 23%; p < 0.001). Moreover, female patients were less often diagnosed fortuitously by routine medical examination (23% vs. 41% in male patients, p < 0.001). Female gender was independently associated with the risk of symptom progression to NYHA functional classes III/IV or death from heart failure or stroke compared with male gender (independent relative hazard 1.5; p < 0.001), particularly patients  50 years of age and with resting outflow obstruction (p < 0.005). Hypertrophic cardiomyopathy-related mortality and risk of sudden death were similar in men and women.
CONCLUSIONS: Women with HCM were under-represented, older, and more symptomatic than men, and showed higher risk of progression to advanced heart failure or death, often associated with outflow obstruction. These gender-specific differences suggest that social, endocrine, or genetic factors may affect the diagnosis and clinical course of HCM. A heightened suspicion for HCM in women may allow for timely implementation of treatment strategies, including relief of obstruction and prevention of sudden death or stroke.
|
Abbreviations and Acronyms
| | HCM = hypertrophic cardiomyopathy | | ICD = implanted cardioverter-defibrillator | | LV = left ventricle/ventricular | | NYHA = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
J. M. Bos, J. A. Towbin, and M. J. Ackerman
Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
201 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Michels, O. I.I. Soliman, M. J. Kofflard, Y. M. Hoedemaekers, D. Dooijes, D. Majoor-Krakauer, and F. J. ten Cate
Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
J. Am. Coll. Cardiol. Img.,
January 1, 2009;
2(1):
58 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Elliott and P Spirito
Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice
Heart,
October 1, 2008;
94(10):
1269 - 1275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schulz-Menger, H. Abdel-Aty, A. Rudolph, T. Elgeti, D. Messroghli, W. Utz, P. Boye, S. Bohl, A. Busjahn, B. Hamm, et al.
Gender-specific differences in left ventricular remodelling and fibrosis in hypertrophic cardiomyopathy: Insights from cardiovascular magnetic resonance
Eur J Heart Fail,
September 1, 2008;
10(9):
850 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Olivotto, M. S. Maron, C. Autore, J. R. Lesser, L. Rega, G. Casolo, M. De Santis, G. Quarta, S. Nistri, F. Cecchi, et al.
Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
559 - 566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Palmer, Y. Wang, P. Teekakirikul, J. T. Hinson, D. Fatkin, S. Strouse, P. VanBuren, C. E. Seidman, J. G. Seidman, and D. W. Maughan
Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex
Am J Physiol Heart Circ Physiol,
April 1, 2008;
294(4):
H1939 - H1947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Blauwet, S. N. Hayes, D. McManus, R. F. Redberg, and M. N. Walsh
Low Rate of Sex-Specific Result Reporting in Cardiovascular Trials
Mayo Clin. Proc.,
February 1, 2007;
82(2):
166 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Hypertrophic Cardiomyopathy in Women
Journal Watch Women's Health,
October 18, 2005;
2005(1018):
8 - 8.
[Full Text]
|
|
|
|
